Miach Orthopaedics secured $40 million in financing to help expand commercialization of the Bridge-Enhanced ACL Restoration, the devicemaker said Jan. 25.
The financing includes $30 million in Series B equity and a $10 million venture debt term sheet, according to a news relese.
The BEAR implant was launched in 2021 and have been used with more than 500 patients, Patrick McBrayer, president and CEO of Miach Orthopaedics, said in the release. The most recent city to add the implant is Buffalo, N.Y. where Peter Gambacorta, DO, completed the debut case.
The BEAR implant uses a patient's own blood to bridge and repair their ACL.